Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

International News In Brief

This article was originally published in The Gray Sheet

Executive Summary

France ups Taxus funding: Reimbursement will be extended to "high-risk" patients in France beginning Nov. 30, according toTaxus paclitaxel-eluting stent manufacturer Boston Scientific. Previously, the only patients eligible for reimbursement were diabetic patients and those whose lesions were located in "small vessels," or vessels with a diameter of less than 3 mm. The expanded coverage will provide funding for patients with long lesions (greater than 15 mm in length) and lesions located in the proximal left anterior descending artery. In France patients are considered to be at high-risk if they have a heightened danger of restenosis, Boston Scientific explains. Also, 4 mm diameter Taxus stents now qualify for funding. The announcement was published Nov. 17 in the Official Journal of the French Government...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT021236

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel